The mixed lymphocyte reaction (MLR) is a classic functional assay that models in vitro interactions between responder T cells and allogeneic antigen-presenting cells (APCs). It quantifies the magnitude and quality of alloreactivity, integrating signals from allorecognition, co-stimulation, inflammatory context, and minor histocompatibility antigens that may not be captured by molecular matching alone. This review is narrative in nature and is intended as a practical, non-systematic synthesis of the field. To provide a modern, practice-oriented synthesis of MLR designs, readouts, and translational uses, highlighting how new technologies have expanded MLR from bulk proliferation into multidimensional immune profiling.We summarize why MLR remains valuable as a functional compatibility probe beyond HLA typing, including the high baseline frequency of alloreactive T cells that produces robust signals without priming. We then review key design options (one-way vs. two-way formats; stimulator inactivation; responder definition; APC source and maturation) and how these choices affect interpretation for rejection and graft-versus-host disease risk modeling, tolerance-focused studies, and immunomodulatory screening. Next, we outline major readouts—radiometric and flow cytometric proliferation (dye dilution, Ki-67), cytokine/chemokine profiling, cytotoxicity adaptations, and next-generation add-ons (e.g., scRNA-seq, TCR sequencing)—emphasizing complementary strengths and common pitfalls. Finally, we consolidate practical quality and reproducibility controls (donor variability, dynamic range, timing, batch effects, and acceptance criteria) to improve cross-study comparability and translational readiness. Modern MLR platforms combine controllable allogeneic stimulation with scalable, high-resolution readouts for mechanistic discovery, immune monitoring and translational immune profiling. Standardized modular design and rigorous quality control can improve reproducibility and support broader adoption across transplantation, immunotherapy, and immune-modulation research.
Galimov et al. (Fri,) studied this question.